SPORE Project 1 Director Awarded NCI Supplement

David DeNardoCongratulations to David DeNardo, PhD, SPORE Project 1 Director, on his recent P30 supplemental research grant from the National Cancer Institute (NCI). Dr. DeNardo's NCI Supplement for Pancreas Cancer Immunotherapy award is a supplement to Dr. Timothy Eberlein’s Cancer Center Support Grant (3P30CA091842) and provides $326,069 in direct costs funding to evaluate combinations of targeted therapies to improve responses to immunotherapy in pancreatic cancer.

The specific aims for the grant include: 1) In human pancreatic ductual adenocarcinomas (PDAC) patients determine the impact of combining focal adhesion kinase (FAK) inhibition and PD1 antagonist on the fibrotic tumor microenvironment, anti-tumor immunity and 2) Determine the efficacy of targeting other members of the FAK signaling network to improve responses to checkpoint immunotherapy.